Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aplidin in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00884286Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Dec 2004
- Primary completion
- Jun 2010
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in non-Hodgkin lymphoma (NHL), sponsored by PharmaMar. Primary endpoint: Objective Response Rate up to 1 year. Started Dec 2004; status: completed.
02
Drugs
plitidepsin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00884286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884286.